Serum TGFBI levels in patients before and after treatment are illustrated in scatter plots in Figure 2A. They were significantly lower in cholangiocarcinoma, hepatocellular carcinoma and gastric carcinoma patients after the treatment than before the treatment. This evidence concerns the gene TGFBI and gastric carcinoma.